Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body.
Study Shows Sharp Decline in Cancer Screenings During First COVID-19 Surge

January 15, 2021 — In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses, researchers at Dana-Farber/Brigham and...
Benefits Manager Policy Disrupts Patient-physician Decision Making for Breast and Prostate Cancer Radiation Treatments

October 2, 2020 — Radiation oncologists expressed serious concerns about a new private insurance coverage policy that could undermine patient-centered care for two of the most common cancers in the United States.
First U.S. Study Shows Promising Outcomes for High-intensity Focused Ultrasound for Prostate Cancer

September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the high-intensity focused ultrasound (HIFU) technology has gained...
CDC Reports Cancer Death Rates Continue to Decline

March 16, 2020 — The Annual Report to the Nation on the Status of Cancer finds that cancer death rates continued to decline from 2001 to 2017 in the United States for all cancer sites combined.

Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds

(L-R) Associate Professor Peter Brotchie (St Vincent's), Dr Ruwan Tennakoon (RMIT), Professor John Thangarajah (RMIT), Dr Mark Page (St Vincent's). Image courtesy of St Vincent's Hospital Melbourne

News | Prostate Cancer | July 19, 2021

New AI Tech for Early Detection of Prostate Cancer

July 19, 2021 — Prostate cancer is the most diagnosed cancer and a leading cause of death by cancer in Australian men....

Most countries have not introduced nationwide prostate cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine, indicates that screening by magnetic resonance imaging (MRI) and targeted biopsies could potentially cut overdiagnoses by half.

Getty Images

News | Prostate Cancer | July 12, 2021

MRI Can Cut Over-diagnoses in Prostate Cancer Screening by Half

July 12, 2021 — Most countries have not introduced nationwide prostate cancer screening, as current methods result in...

The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

Image courtesy of JNM

News | PET Imaging | June 28, 2021

FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate...

A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.

Figure 1. Case example: A 54-year-old man with a history of RP+LND and a subsequent PSA of 1.25 ng/mL had no evidence of disease by baseline imaging. Piflufolastat F 18 (18F-DCFPyL)- PET/CT accurately detected biochemically recurrent prostate cancer with the PSMA PET/CT scan identifying positive left (left panel) and right peri-rectal lymph nodes (right panel).

News | Prostate Cancer | June 21, 2021

PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

June 21, 2021 — A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (...

#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021

Decrease in Prostate Cancer Diagnoses Due to Pandemic

April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer...

A new study led by Ivan Martinez—associate professor in the WVU School of Medicine and Cancer Institute—found a link between a family of RNAs, the Y chromosome, and radiation sensitivity in male lung-cancer patients

News | Radiation Therapy | March 23, 2021

Loss of Y chromosome, RNA Tied to Radiation Resistance in Male Lung-cancer Patients

March 23, 2021 — The science behind the COVID-19 vaccine has the potential to do more than prevent cases of COVID-19...

A national screening program targeted at those men who are genetically pre-disposed to prostate cancer, and involving a blood test and magnetic resonance imaging (MRI) scan before an invasive biopsy, could prevent one in six prostate cancer deaths and significantly reduce over-diagnosis, finds a new study led by UCL researchers.

Getty Images

News | Prostate Cancer | March 15, 2021

Targeted Screening for Prostate Cancer Could Prevent One in Six Deaths

March 15, 2021 — A national screening program targeted at those men who are genetically pre-disposed to prostate cancer...

Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.

Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.

Feature | Treatment Planning | March 05, 2021 | By Melinda Taschetta-Millane

Using PET to Enhance Prostate Treatment Planning

The decision to offer radiation after prostatectomy for patients with recurrent prostate cancer is quite complex, and...

Immunotherapy-based precision medicine clinical trials being developed

Getty Images

News | Prostate Cancer | February 16, 2021

Why Black Men's Prostate Cancer May be More Responsive to Immunotherapy

February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits from...

The Milton and Caroll Petrie Department of Urology at Mount Sinai has received a $3.8 million donation from philanthropist Robert F. Smith to launch the Robert F. Smith Mobile MRI Unit in partnership with the Mount Sinai Health System to support prostate health in the Black community.

Getty Images

News | Prostate Cancer | February 12, 2021

Mount Sinai Receives $3.8 Million Gift to Launch Mobile MRI Unit to Support Prostate Health in the Black Community

February 12, 2021 — The Milton and Caroll Petrie Department of Urology at Mount Sinai has received a $3.8 million...

Phase III clinical trial of men with a clinical suspicion of prostate cancer finds MRI with targeted biopsies to be more accurate at diagnosis and less intrusive than current standard

News | Magnetic Resonance Imaging (MRI) | February 08, 2021

Using MRI for Prostate Cancer Diagnosis Equals or Beats Current Standard

February 8, 2021 — The results of a Phase III randomized clinical trial have shown that when it comes to detecting...

Images in 69-year-old man with biopsy-confirmed Gleason score 7 (3+4) prostate cancer. (a) Pretreatment axial T2-weighted fast spin-echo MRI scan (repetition time msec/echo time msec, 3820/97) shows tumor in midline anterior transition zone (arrow). (b) Intraoperative MRI scan shows contoured rectal wall (red line), prostate margin (blue outline), and region of interest (orange outline). Because the urethra was included in planned treatment volume, a suprapubic catheter was placed for continuous bladder drainage during treatment. (c) Intraoperative MRI scan shows focused ultrasound beam path (blue) overlaid on treatment plan. Rectangles illustrate each sonication spot. (d) Thermal map image obtained during treatment with heat deposition color coded in red overlaid on sonication spot. (e) Axial gadopentetate dimeglumine-enhanced MRI scan (230/2.97) obtained immediately after treatment shows devascularized ablated volume (arrows). (f) Corresponding T2-weighted fast spin-echo MRI scan (3820/97) at 5 months after ablation shows complete involution of transition zone. All seven cores from treatment area margins were negative for cancer at biopsy. Image courtesy of the Radiological Society of North America

News | Prostate Cancer | February 05, 2021

Ultrasound Technique Treats Prostate Cancer with Minimal Side Effects

February 5, 2021 — A technique that delivers high-intensity focused ultrasound to targeted tissue under MRI guidance...

An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost, as shown by a large-scale study initiated by UMC Utrecht in collaboration with the Netherlands Cancer Institute, UZ Leuven and Radboudumc.

News | Prostate Cancer | January 25, 2021

Radiation Boost Lowers Risk of Prostate Cancer Recurrence

January 25, 2021 — An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects...

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.

Detecting Prostate Cancer With Advanced Micro-ultrasound

Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next...

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021

Study Shows Sharp Decline in Cancer Screenings During First COVID-19 Surge

January 15, 2021 — In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses,...

The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021

US Prostate Cancer Nuclear Medicine Diagnostics Market Outlook

January 13, 2021 — The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast...

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021

MRI Frequently Underestimates Tumor Size in Prostate Cancer

January 11, 2021 — A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic...